StockNews.com upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a buy rating to a strong-buy rating in a research report released on Tuesday.
Separately, Needham & Company LLC restated a buy rating and set a $47.00 target price on shares of Surmodics in a report on Wednesday, April 10th.
Get Our Latest Analysis on Surmodics
Surmodics Stock Up 0.7 %
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Los Angeles Capital Management LLC boosted its holdings in Surmodics by 149.2% during the third quarter. Los Angeles Capital Management LLC now owns 34,916 shares of the company’s stock worth $1,120,000 after purchasing an additional 20,906 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in Surmodics in the third quarter valued at $683,000. Acadian Asset Management LLC lifted its stake in Surmodics by 18.8% in the third quarter. Acadian Asset Management LLC now owns 354,738 shares of the company’s stock valued at $11,377,000 after acquiring an additional 56,012 shares during the last quarter. Moody National Bank Trust Division lifted its stake in Surmodics by 14.8% in the fourth quarter. Moody National Bank Trust Division now owns 10,341 shares of the company’s stock valued at $376,000 after acquiring an additional 1,331 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Surmodics in the fourth quarter valued at $163,000. Institutional investors and hedge funds own 96.63% of the company’s stock.
Surmodics Company Profile
Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).
See Also
- Five stocks we like better than Surmodics
- Dividend Payout Ratio Calculator
- Silicon Motion Proves That AI in Motion Stays in Motion
- 3 Best Fintech Stocks for a Portfolio Boost
- Undervalued UnitedHealth Group Won’t Be For Long
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with MarketBeat.com's FREE daily email newsletter.